Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 6/20 | 0.62 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL359350 | 0.82 | CYP17A1 (0.65) | CYP17A1GRM1MEN1KMT2AMAPT | |
| SCHEMBL368288 | 0.78 | CYP17A1 (0.73) | CYP17A1GRM1CYP1A2 | |
| SCHEMBL5967241 | 0.77 | CYP17A1 (1.00) | CYP17A1GRM1MEN1KMT2AMAPT | |
| SCHEMBL10187247 | 0.76 | CYP17A1 (1.00) | CYP17A1GRM1MEN1KMT2AKDM4E | |
| SCHEMBL368895 | 0.76 | CYP17A1 (0.78) | CYP17A1GRM1MEN1KMT2AKDM4E | |
| SCHEMBL369078 | 0.75 | CYP17A1 (0.69) | CYP17A1GRM1MEN1KMT2ACYP1A2 | |
| SCHEMBL5967641 | 0.75 | CYP17A1 (1.00) | CYP17A1GRM1MEN1KMT2AMAPT | |
| SCHEMBL10076704 | 0.74 | CYP17A1 (1.00) | CYP17A1GRM1MEN1KMT2ACYP1A2 | |
| SCHEMBL368955 | 0.71 | CYP17A1 (0.57) | CYP17A1MAPTNPC1RAB9ATP53 | |
| SCHEMBL10188361 | 0.71 | CYP17A1 (0.44) | CYP17A1MAPTALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266880-B2 | Substituted azaindazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266880-B2 | Substituted azaindazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266880-B2 | Substituted azaindazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-23 | — | — | US | disclosed |
| EP-2638041-B1 | SUBSTITUTED AZAINDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2015-07-22 | — | — | EP | disclosed |
| EP-2638041-B1 | SUBSTITUTED AZAINDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2015-07-22 | — | — | EP | disclosed |
| EP-2593453-B1 | AZAINDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-17 | — | — | EP | disclosed |
| EP-2593453-B1 | AZAINDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-17 | — | — | EP | disclosed |
| US-8673922-B2 | Azaindazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673922-B2 | Azaindazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673922-B2 | Azaindazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130231354-A1 | SUBSTITUTED AZAINDAZOLE COMPOUNDS | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231354-A1 | SUBSTITUTED AZAINDAZOLE COMPOUNDS | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130184254-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2013-07-18 | — | — | US | disclosed |
| US-20130184254-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2013-07-18 | — | — | US | disclosed |
| US-20130184254-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2013-07-18 | — | — | US | disclosed |
| EP-2593453-A1 | AZAINDAZOLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012064815-A1 | SUBSTITUTED AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012064815-A1 | SUBSTITUTED AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012009510-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012009510-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231354-A1 | SUBSTITUTED AZAINDAZOLE COMPOUNDS | CYP3A7, CYP2C19, UGT2B17 | CYP17A1 45/4885GRM1 3030/4885MEN1 2788/4885 |
| US-20130184254-A1 | AZAINDAZOLE COMPOUNDS | CYP3A4, CYP4B1, CYP3A43 | CYP17A1 53/4885GRM1 3351/4885MEN1 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.